RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Withdrawn trial aimed to pit One-Time cell therapy against chemo for Tough-to-Treat lymphoma
Disease control TerminatedThis trial aimed to see if a one-time CAR-T cell therapy (liso-cel) worked better and was safer than standard chemotherapy for adults whose follicular lymphoma had returned or stopped responding to prior treatments. It was a large, global Phase 3 study that would have randomly as…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo challenges standard treatment for blood cancer
Disease control OngoingThis study compares two different drug combinations for people with follicular lymphoma that has returned or stopped responding to previous treatment. Researchers want to see if a newer drug called mosunetuzumab works better than the standard drug rituximab when both are given wi…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC